Cefdinir

Pharmacologic Category

Antibiotic, Cephalosporin (Third Generation)

Dosing: Adult

Chronic obstructive pulmonary disease, exacerbation: Oral: 300 mg twice daily or 600 mg once daily for 5 to 7 days (Bartlett 2018; GOLD 2019). Note: Some experts reserve for use in patients with uncomplicated chronic obstructive pulmonary disease (eg, age <65 years of age without major comorbidities, FEV₁ >50% predicted, infrequent exacerbations) (Anzueto 2007; Sethi 2008).

Otitis media, acute (alternative agent for mild [non-anaphylactic] penicillin allergy): Limited data available: Oral: 300 mg twice daily or 600 mg once daily; duration of therapy is 5 to 7 days (mild to moderate infection) or 10 days (severe infection) (Limb 2019; manufacturer's labeling).

Streptococcal pharyngitis (group A) (alternative agent for mild [non-anaphylactic] penicillin allergy): Oral: 300 mg twice daily for 5 to 10 days or 600 mg once daily for 10 days (Pichichero 2020; manufacturer's labeling).

Urinary tract infection (UTI) (alternative agent) (off-label use): Note: Use only when preferred agents cannot be used (due to limited evidence and decreased efficacy of oral beta-lactams compared to other agents) (IDSA/ESCMID [Gupta 2011]; Hooton 2018a; Hooton 2018b; Hooton 2018c).

Acute uncomplicated cystitis or acute simple cystitis (infection limited to bladder and no signs/symptoms of upper tract, prostate, or systemic infection): Oral: 300 mg twice daily for 5 to 7 days (IDSA/ESCMID [Gupta 2011]; Hooton 2018b; Hooton 2018c).

UTI, complicated, including pyelonephritis: Oral: 300 mg twice daily for 10 to 14 days. Note: Oral therapy should follow appropriate parenteral therapy and patients should be monitored closely. For outpatient treatment of mild infection, a single dose of a long-acting parenteral agent is acceptable before transitioning to oral therapy (IDSA/ESCMID [Gupta 2011]; Hooton 2018a).

* See Dosage and Administration in AHFS Essentials for additional information.

Dosing: Geriatric

Refer to adult dosing.

Dosing: Renal Impairment: Adult

CrCl ≥30 mL/minute: No dosage adjustment necessary.

CrCl <30 mL/minute: Oral: 300 mg once daily

ESRD requiring intermittent hemodialysis (IHD): Dialyzable: (63%): Oral: Initial dose: 300 mg (or 7 mg/kg/dose) every other day. Postdialysis, 300 mg (or 7 mg/kg/dose) should be given. Subsequent doses (300 mg or 7 mg/kg/dose) should be administered every other day.

Dosing: Hepatic Impairment: Adult

No dosage adjustment necessary.

Dosing: Pediatric

General dosing, susceptible infection (Red Book 2012): Mild to moderate infections: Infants, Children, and Adolescents: Oral: 14 mg/kg/day in divided doses 1 to 2 times daily; maximum daily dose: 600 mg/day

Bronchitis, acute exacerbation: Oral: Adolescents: 300 mg every 12 hours for 5 to 10 days or 600 mg every 24 hours for 10 days

Otitis media, acute: Infants ≥6 months and Children: Oral: 14 mg/kg/day in divided doses every 12 to 24 hours for 5 to 10 days; maximum daily dose: 600 mg/day. Variable duration of therapy: If <2 years of age or severe symptoms (any age): 10-day course; if 2 to 5 years of age with mild to moderate symptoms: 7-day course; if ≥6 years of age with mild to moderate symptoms: 5- to 7-day course (AAP [Lieberthal 2013]). Note: Recommended by the AAP as an alternative agent for initial treatment in penicillin allergic patients (AAP [Lieberthal 2013]).

Pharyngitis/Tonsillitis: Note: Although FDA approved at twice daily dosing, duration <10 days is not recommended (Shulman 2012).

Infants ≥6 months and Children: Oral: 7 mg/kg/dose every 12 hours for 5 to 10 days or 14 mg/kg/dose every 24 hours for 10 days; maximum daily dose: 600 mg/day

Adolescents: Oral: 300 mg every 12 hours for 5 to 10 days or 600 mg every 24 hours for 10 days

Pneumonia, community-acquired: Adolescents: Oral: 300 mg every 12 hours for 10 days

Skin and skin structure infection, uncomplicated:

Infants ≥6 months and Children: Oral: 14 mg/kg/day in divided doses twice daily for 10 days; maximum daily dose: 600 mg/day

Adolescents: Oral: 300 mg every 12 hours for 10 days

Sinusitis, acute maxillary: Note: Due to decreased S. pneumonia sensitivity, cefdinir is no longer recommended as monotherapy for the initial empiric treatment of sinusitis (Chow 2012)

Infants ≥6 months and Children: Oral: 14 mg/kg/day in divided doses every 12 to 24 hours for 10 days; maximum daily dose: 600 mg/day

Adolescents: Oral: 300 mg every 12 hours or 600 mg every 24 hours for 10 days

Dosing: Renal Impairment: Pediatric

Infants ≥6 months and Children:

CrCl ≥30 mL/minute/1.73 m²: No adjustment required

CrCl <30 mL/minute/1.73 m²: 7 mg/kg/dose once daily; maximum daily dose: 300 mg/day

Adolescents:

CrCl ≥30 mL/minute: No adjustment required

CrCl <30 mL/minute: 300 mg once daily

Hemodialysis: Dialyzable (63%): Infants ≥6 months, Children, and Adolescents: Initial dose: 7 mg/kg/dose (maximum dose: 300 mg) every other day. At the conclusion of each hemodialysis session, an additional dose (7 mg/kg/dose up to 300 mg) should be given. Subsequent doses should be administered every other day.

Dosing: Hepatic Impairment: Pediatric

There are no dosing adjustments provided in the manufacturer's labeling (has not been studied).

Calculations

Use: Labeled Indications

Chronic obstructive pulmonary disease, exacerbation: Treatment of acute exacerbations of chronic bronchitis in adults and adolescents caused by Haemophilus influenzae (including beta-lactamase-producing strains), Haemophilus parainfluenzae (including beta-lactamase-producing strains), Streptococcus pneumoniae (penicillin-susceptible strains only), and Moraxella catarrhalis (including beta-lactamase-producing strains)

Otitis media, acute: Treatment of acute bacterial otitis media in pediatric patients caused by H. influenzae (including beta-lactamase-producing strains), S. pneumoniae (penicillin-susceptible strains only), and M. catarrhalis (including beta-lactamase-producing strains)

Pneumonia, community-acquired: Treatment of community-acquired pneumonia in adults and adolescents caused by H. influenzae (including beta-lactamase-producing strains), H. parainfluenzae (including beta-lactamase-producing strains), S. pneumoniae (penicillin-susceptible strains only), and M. catarrhalis (including beta-lactamase-producing strains)

Sinusitis, acute: Treatment of acute maxillary sinusitis in adults and adolescents caused by H. influenzae (including beta-lactamase-producing strains), S. pneumoniae (penicillin-susceptible strains only), and M. catarrhalis (including beta-lactamase-producing strains). Note: Limitations of use: According to the IDSA guidelines for acute bacterial rhinosinusitis, cefdinir is no longer recommended as monotherapy for initial empiric treatment (IDSA [Chow 2012]).

Skin and skin structure infections, uncomplicated: Treatment of uncomplicated skin and skin structure infections in adults, adolescents, and pediatric patients caused by Staphylococcus aureus (including beta-lactamase-producing strains) and Streptococcus pyogenes

Streptococcal pharyngitis (group A): Treatment of pharyngitis/tonsillitis in adults, adolescents, and pediatric patients caused by S. pyogenes

* See Uses in AHFS Essentials for additional information.

Use: Off-Label: Adult

Urinary tract infection, complicated, including pyelonephritisLevel of Evidence [C]

Clinical experience suggests the utility of cefdinir as an alternative agent in the treatment of acute complicated UTI (including pyelonephritis) after administration of an appropriate parenteral agent ^Ref.

Urinary tract infection, acute uncomplicated cystitis or acute simple cystitisLevel of Evidence [C, G]

Clinical experience suggests the utility of cefdinir as an alternative agent in the treatment of acute simple cystitis (infection limited to the bladder and no signs/symptoms of upper tract or systemic infections) ^Ref.

Based on the Infectious Diseases Society of America and European Society for Microbiology and Infectious Diseases (IDSA/ESCMID) international clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women, cefdinir is an effective and recommended alternative agent in the management of acute uncomplicated cystitis ^Ref.

Level of Evidence Definitions

Level of Evidence Scale

Class and Related Monographs

Cephalosporins

Clinical Practice Guidelines

Bacterial Rhinosinusitis, Acute:

IDSA, “Clinical Practice Guideline for Acute Bacterial Rhinosinusitis in Children and Adults,” 2012

Chronic Obstructive Pulmonary Disease:

GOLD, “Global Strategy for Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease,” 2019

Pneumonia, Community-Acquired:

IDSA/PIDS, "The Management of Community-Acquired Pneumonia in Infants and Children Older Than 3 Months of Age," 2011

Urinary Tract Infections:

IDSA, “International Clinical Practice Guidelines for the Treatment of Acute Uncomplicated Cystitis and Pyelonephritis in Women,” March 2011

Administration: Oral

Twice daily doses should be given every 12 hours. May be administered with or without food. Manufacturer recommends administering at least 2 hours before or after antacids or iron supplements. Shake suspension well before use.

Administration: Pediatric

Oral: May administer with or without food; administer with food if stomach upset occurs; administer cefdinir at least 2 hours before or after antacids or iron supplements; shake suspension well before use.

Storage/Stability

Store at 20°C to 25°C (68°F to 77°F). Store reconstituted suspension at room temperature 20°C to 25°C (68°F to 77°F) for 10 days.

Preparation for Administration: Adult

Refer to manufacturer’s product labeling for reconstitution instructions.

Preparation for Administration: Pediatric

Oral: Reconstitute powder for oral suspension with appropriate amount of water as specified on the bottle. Shake vigorously until suspended.

Medication Patient Education with HCAHPS Considerations

What is this drug used for?

• It is used to treat bacterial infections.

Frequently reported side effects of this drug

• Diarrhea

Other side effects of this drug: Talk with your doctor right away if you have any of these signs of:

• Bruising

• Bleeding

• Not able to pass urine

• Change in amount of urine passed

• Dark urine

• Yellow skin or eyes

• Chills

• Sore throat

• Severe loss of strength and energy

• Seizures

• Clostridioides (formerly Clostridium) difficile-associated diarrhea like abdominal pain or cramps, severe diarrhea or watery stools, or bloody stools

• Signs of a significant reaction like wheezing; chest tightness; fever; itching; bad cough; blue skin color; seizures; or swelling of face, lips, tongue, or throat.

Note: This is not a comprehensive list of all side effects. Talk to your doctor if you have questions.

Consumer Information Use and Disclaimer: This information should not be used to decide whether or not to take this medicine or any other medicine. Only the healthcare provider has the knowledge and training to decide which medicines are right for a specific patient. This information does not endorse any medicine as safe, effective, or approved for treating any patient or health condition. This is only a brief summary of general information about this medicine. It does NOT include all information about the possible uses, directions, warnings, precautions, interactions, adverse effects, or risks that may apply to this medicine. This information is not specific medical advice and does not replace information you receive from the healthcare provider. You must talk with the healthcare provider for complete information about the risks and benefits of using this medicine.

Contraindications

Hypersensitivity to cefdinir, any component of the formulation, or other cephalosporins.

Warnings/Precautions

Concerns related to adverse effects:

• Penicillin allergy: Use with caution in patients with a history of penicillin allergy, especially IgE-mediated reactions (eg, anaphylaxis, angioedema, urticaria).

• Superinfection: Prolonged use may result in fungal or bacterial superinfection, including C. difficile-associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed >2 months postantibiotic treatment.

Disease-related concerns:

• Colitis: Use with caution in patients with a history of colitis.

• Renal impairment: Use with caution in patients with renal impairment (CrCl <30 mL/minute); dosage adjustment may be required.

Concurrent drug therapy issues:

• Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.

• Iron-containing products: Cases of reddish stools have been reported with concomitant use of cefdinir and iron-containing products due to the formation of a nonabsorbable complex in the GI tract.

* See Cautions in AHFS Essentials for additional information.

Geriatric Considerations

Cefdinir has not been studied exclusively in the elderly. Patients ≥65 years of age have been included in clinical trials. No information is available on the elderly's response or tolerance.

Warnings: Additional Pediatric Considerations

Iron-containing infant formulas do not affect the pharmacokinetics of cefdinir but may result in the development of red-appearing, nonbloody stools; this occurs when cefdinir is coadministered with iron-containing products and an insoluble iron-cefdinir complex forms; patients/parents should be counseled. Administer cautiously to penicillin-sensitive patients, especially IgE-mediated reactions (eg, anaphylaxis, urticaria). Prolonged use may result in fungal or bacterial superinfection, including C. difficile-associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed >2 months postantibiotic treatment. Use with caution in patients with a history of colitis. Use caution with renal dysfunction (CrCl <30 mL/minute); dose adjustment may be required. Potentially significant drug-drug interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy.

Pregnancy Risk Factor

Pregnancy Considerations

Teratogenic events have not been observed in animal reproduction studies. An increase in most types of birth defects was not found following first trimester exposure to cephalosporins.

Breast-Feeding Considerations

Cefdinir was not detectable in breast milk following a single cefdinir 600 mg dose. In general, if antibiotics are present in breast milk, nondose-related modification of bowel flora may occur. Monitor infants for GI disturbances, such as thrush and diarrhea (WHO 2002).

Lexicomp Pregnancy & Lactation, In-Depth

Cefdinir

Briggs' Drugs in Pregnancy & Lactation

Cefdinir

Adverse Reactions

>10%: Gastrointestinal: Diarrhea (8% to 15%)

1% to 10%:

Central nervous system: Headache (2%)

Dermatologic: Skin rash (≤3%)

Endocrine & metabolic: Decreased serum bicarbonate (≤1%), glycosuria (≤1%), hyperglycemia (≤1%), hyperphosphatemia (≤1%), increased gamma-glutamyl transferase (≤1%), increased lactate dehydrogenase (≤1%)

Gastrointestinal: Nausea (≤3%), abdominal pain (≤1%), vomiting (≤1%)

Genitourinary: Vulvovaginal candidiasis (≤4%), urine abnormality (increased leukocytes: ≤2%), proteinuria (1% to 2%), occult blood in urine (≤1%), vaginitis (≤1%)

Hematologic & oncologic: Lymphocytosis (≤2%), eosinophilia (1%), lymphocytopenia (1%), abnormal neutrophils (functional disorder of polymorphonuclear neutrophils: ≤1%), thrombocythemia (≤1%), change in WBC count (≤1%)

Hepatic: Increased serum alkaline phosphatase (≤1%), increased serum ALT (≤1%)

Renal: Increased urine pH (≤1%), increased urine specific gravity (≤1%)

<1%, postmarketing, and/or case reports: Abnormal stools, anaphylaxis, anorexia, asthma, blood coagulation disorder, bloody diarrhea, candidiasis, cardiac failure, chest pain, cholestasis, conjunctivitis, constipation, cutaneous candidiasis, decreased hemoglobin, decreased urine specific gravity, disseminated intravascular coagulation, dizziness, drowsiness, dyspepsia, enterocolitis (acute), eosinophilic pneumonitis, erythema multiforme, erythema nodosum, exfoliative dermatitis, facial edema, fever, flatulence, fulminant hepatitis, granulocytopenia, hemolytic anemia, hemorrhagic colitis, hemorrhagic diathesis, hepatic failure, hepatitis (acute), hyperkalemia, hyperkinesia, hypersensitivity angiitis, hypertension, hypocalcemia, hypophosphatemia, immune thrombocytopenia, increased amylase, increased blood urea nitrogen, increased monocytes, increased serum AST, increased serum bilirubin, insomnia, interstitial pneumonitis (idiopathic), intestinal obstruction, involuntary body movements, jaundice, laryngeal edema, leukopenia, leukorrhea, loss of consciousness, maculopapular rash, melena, myocardial infarction, pancytopenia, peptic ulcer, pneumonia (drug-induced), pruritus, pseudomembranous colitis, renal disease, renal failure (acute), respiratory failure (acute), rhabdomyolysis, serum sickness, shock, Stevens-Johnson syndrome, stomatitis, thrombocytopenia, toxic epidermal necrolysis, upper gastrointestinal hemorrhage, weakness, xerostomia

* See Cautions in AHFS Essentials for additional information.

Allergy and Idiosyncratic Reactions

Cephalosporin Allergy

Metabolism/Transport Effects

None known.

Drug Interactions Open Interactions

Aminoglycosides: Cephalosporins (3rd Generation) may enhance the nephrotoxic effect of Aminoglycosides. Risk C: Monitor therapy

BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). Risk X: Avoid combination

BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). Risk C: Monitor therapy

Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine. Management: Avoid cholera vaccine in patients receiving systemic antibiotics, and within 14 days following the use of oral or parenteral antibiotics. Risk X: Avoid combination

Iron Preparations: May decrease the serum concentration of Cefdinir. Red-appearing, non-bloody stools may also develop due to the formation of an insoluble iron-cefdinir complex. Management: Avoid concurrent cefdinir and oral iron when possible. Separating doses by several hours may minimize interaction. Iron-containing infant formulas do not appear to interact with cefdinir. Exceptions: Ferric Carboxymaltose; Ferric Derisomaltose; Ferric Gluconate; Ferric Hydroxide Polymaltose Complex; Ferric Pyrophosphate Citrate; Ferumoxytol; Iron Dextran Complex; Iron Sucrose. Risk D: Consider therapy modification

Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. Risk C: Monitor therapy

Multivitamins/Minerals (with ADEK, Folate, Iron): May decrease the serum concentration of Cefdinir. Specifically, Iron Salts may decrease the serum concentration of Cefdinir. Red-appearing, non-bloody stools may also develop due to the formation of an insoluble iron-cefdinir complex. Management: Avoid concurrent cefdinir and oral iron-containing multivitamins when possible. Separating doses by several hours may minimize interaction. Iron-containing infant formulas do not appear to interact with cefdinir. Risk D: Consider therapy modification

Probenecid: May increase the serum concentration of Cephalosporins. Risk C: Monitor therapy

Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate. Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic. Risk D: Consider therapy modification

Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected. Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents. Use of this vaccine should be postponed until at least 3 days after cessation of antibacterial agents. Risk D: Consider therapy modification

Vitamin K Antagonists (eg, warfarin): Cephalosporins may enhance the anticoagulant effect of Vitamin K Antagonists. Risk C: Monitor therapy

Test Interactions

False-positive reaction for urinary ketones may occur with nitroprusside- but not nitroferricyanide-based tests. False-positive urine glucose results may occur when using Clinitest®, Benedict's solution, or Fehling’s solution; glucose-oxidase-based reaction systems (eg, Clinistix®, Tes-Tape®) are recommended. May cause positive direct Coombs’ test.

Monitoring Parameters

Monitor renal function. Observe for signs and symptoms of anaphylaxis during first dose.

Advanced Practitioners Physical Assessment/Monitoring

Assess results of culture/sensitivity tests and patient's allergy history prior to therapy. Teach patient to report opportunistic infection and hypersensitivity.

Nursing Physical Assessment/Monitoring

Results of culture/sensitivity tests and patient's allergy history should be assessed prior to therapy. Teach patient to report opportunistic infection and hypersensitivity.

Dosage Forms: US

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Capsule, Oral:

Generic: 300 mg

Suspension Reconstituted, Oral:

Generic: 125 mg/5 mL (60 mL, 100 mL); 250 mg/5 mL (60 mL, 100 mL)

Dosage Forms: Canada

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Capsule, Oral:

Omnicef: 300 mg

Suspension Reconstituted, Oral:

Omnicef: 125 mg/5 mL (60 mL, 100 mL)

Anatomic Therapeutic Chemical (ATC) Classification

J01DD15

Generic Available (US)

Yes

Pricing: US

Capsules (Cefdinir Oral)

300 mg (per each): $5.11

Suspension (reconstituted) (Cefdinir Oral)

125 mg/5 mL (per mL): $0.85

250 mg/5 mL (per mL): $1.66

Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.

Mechanism of Action

Inhibits bacterial cell wall synthesis by binding to one or more of the penicillin-binding proteins (PBPs) which in turn inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell walls, thus inhibiting cell wall biosynthesis. Bacteria eventually lyse due to ongoing activity of cell wall autolytic enzymes (autolysins and murein hydrolases) while cell wall assembly is arrested.

Pharmacodynamics/Kinetics

Distribution: Penetrates into blister fluid, middle ear fluid, tonsils, sinus, and lung tissues; V_d:

Children 6 months to 12 years: 0.67 ± 0.38 L/kg

Adults: 0.35 ± 0.29 L/kg

Protein binding: 60% to 70%

Metabolism: Minimal

Bioavailability: Capsule: 16% to 21%; suspension 25%

Half-life elimination: 1.7 (± 0.6) hours with normal renal function

Time to peak, plasma: 2 to 4 hours

Excretion: Primarily urine (~12% to 18% as unchanged drug)

Pharmacodynamics/Kinetics: Additional Considerations

Renal function impairment: Clearance is reduced.

Local Anesthetic/Vasoconstrictor Precautions

No information available to require special precautions

Effects on Dental Treatment

Key adverse event(s) related to dental treatment: Rare occurrences of stomatitis, candidiasis, erythema multiforme, Stevens-Johnson syndrome, facial edema, and xerostomia have been reported.

Effects on Bleeding

No information available to require special precautions

Index Terms

CFDN; Omnicef

FDA Approval Date

December 04, 1997

References

American Academy of Pediatrics (AAP). In: Pickering LK, Baker CJ, Kimberlin DW, Long SS, eds. Red Book: 2012 Report of the Committee on Infectious Diseases. 29th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2012.

Anzueto A, Sethi S, Martinez FJ. Exacerbations of chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2007;4(7):554-564.[PubMed 17878469]

Bartlett JG, Sethi S. Management of infection in exacerbations of chronic obstructive pulmonary disease. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed September 24, 2018.

Bradley JS, Byington CL, Shah SS, et al. The Management of Community-Acquired Pneumonia in Infants and Children Older Than 3 Months of Age: Clinical Practice Guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America. Clin Infect Dis, 2011, 53(7):e25-76.[PubMed 21880587]

Cefdinir capsules [prescribing information]. BluePoint Laboratories; February 2016.

Cefdinir for oral suspension [prescribing information]. North Wales, PA; Teva Pharmaceuticals USA, Inc; July 2018.

Chow AW, Benninger MS, Brook I, et al; Infectious Diseases Society of America. IDSA clinical practice guideline for acute bacterial rhinosinusitis in children and adults. Clin Infect Dis. 2012;54(8):e72-e112.[PubMed 22438350]

Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease: 2019 Report. Global Initiative for Chronic Obstructive Lung Disease website. https://goldcopd.org/wp-content/uploads/2018/11/GOLD-2019-v1.7-FINAL-14Nov2018-WMS.pdf. Published 2019. Accessed July 25, 2019.

Gupta K, Hooton TM, Naber KG, et al; Infectious Diseases Society of America; European Society for Microbiology and Infectious Diseases. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis. 2011;52(5):e103-e120.[PubMed 21292654]10.1093/cid/ciq257

Hooton TM, Gupta K. Acute complicated urinary tract infection (including pyelonephritis) in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed October 8, 2018a.

Hooton T, Kalpana G. Acute simple cystitis in women. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed February 22, 2018b.

Hooton T. Acute simple cystitis in men. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed February 22, 2018c.

Klein JO and McCracken GH Jr, “Summary: Role of a New Oral Cephalosporin, Cefdinir, for Therapy of Infections of Infants and Children,” Pediatr Infect Dis J, 2000, 19(12 Suppl):S181-3.[PubMed 11144402]

Lieberthal AS, Carroll AE, Chonmaitree T, et al, "The Diagnosis and Management of Acute Otitis Media," Pediatrics, 2013, 131(3):e964-99.[PubMed 23439909]

Limb CJ, Lustig LR, Durand M. Acute otitis media in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed August 6, 2019.

Perry CM and Scott LJ, "Cefdinir: A Review of Its Use in the Management of Mild-to-Moderate Bacterial Infections," Drugs, 2004, 64(13):1433-64.[PubMed 15212560]

Pichichero ME. Treatment and prevention of streptococcal pharyngitis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed February 12, 2020.

Sethi S, Murphy TF. Infection in the pathogenesis and course of chronic obstructive pulmonary disease. N Engl J Med. 2008;359(22):2355-2365. doi: 10.1056/NEJMra0800353.[PubMed 19038881]

Shulman ST, Bisno AL, Clegg HW, et al, "Clinical Practice Guideline for the Diagnosis and Management of Group A Streptococcal Pharyngitis: 2012 Update by the Infectious Diseases Society of America," Clin Infect Dis, 2012. Available at http://aapredbook.aappublications.org/cgi/content/full

World Health Organization (WHO). Breastfeeding and maternal medication, recommendations for drugs in the Eleventh WHO Model List of Essential Drugs. 2002. Available at http://www.who.int/maternal_child_adolescent/documents/55732/en.[PubMed 23215911]

Brand Names: International

Adcef (IN); Addcef (VN); Adinir (BD); Anicef (KR); Anycef (KR); Cedenir (EG); Cednir (BD); Cefdiar (KR); Cefnaxl (PH); Cefnir (BD, PK); Cefralin (PE); Cefzon (CN, JP); Celofarm (CL); Danircap (VN); Haginir DT (VN); Kefnir (MY, VN); Maxdinir (EG); Medsidin (VN); Nilocef (BD); Nircef (ID); Nirocef (PH); Omicef (PH); Omnicef (AE, BB, BH, BM, BS, BZ, CY, EG, GY, ID, IL, IQ, IR, JM, JO, KR, KW, LB, LY, NL, OM, PR, QA, SA, SE, SR, SY, TH, TT, VN, YE); Omnicef R (CR, DO, GT, HN, NI, PA, SV); Orcef-DS (PH); Samnir (TH); Sefarin (LB); Sefdin (IN); Sefdy (PH); Torbener (EG); Trinir (PH)

Last Updated 3/14/20

Google Sites

Report abuse